Volume 37 Issue 11, November 2019
Editorial | 05 November 2019
The next biotech superpower
China is set to challenge the pre-eminence of the US drug market. If it can address gaps in its R&D ecosystem and clinical infrastructure, it may even become a home for biotech innovators.